Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Position Increased by Rafferty Asset Management LLC

Rafferty Asset Management LLC increased its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating) by 89.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 376,577 shares of the biopharmaceutical company’s stock after purchasing an additional 177,395 shares during the period. Rafferty Asset Management LLC owned 0.26% of Sangamo Therapeutics worth $2,824,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Brown Advisory Inc. acquired a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $76,000. Assenagon Asset Management S.A. bought a new stake in shares of Sangamo Therapeutics during the 4th quarter worth $94,000. E Fund Management Co. Ltd. bought a new stake in shares of Sangamo Therapeutics during the 3rd quarter worth $100,000. Aries Wealth Management bought a new stake in shares of Sangamo Therapeutics during the 4th quarter worth $105,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Sangamo Therapeutics during the 3rd quarter worth $111,000. 52.40% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics stock opened at $3.95 on Wednesday. The business’s 50-day simple moving average is $5.15 and its 200-day simple moving average is $6.57. The firm has a market capitalization of $579.41 million, a PE ratio of -3.24 and a beta of 1.63. Sangamo Therapeutics, Inc. has a 52 week low of $3.48 and a 52 week high of $12.83.

Sangamo Therapeutics (NASDAQ:SGMOGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. Sangamo Therapeutics had a negative return on equity of 43.12% and a negative net margin of 156.53%. The firm had revenue of $28.20 million for the quarter, compared to analyst estimates of $27.29 million. During the same period in the previous year, the company posted ($0.32) earnings per share. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, analysts predict that Sangamo Therapeutics, Inc. will post -1.41 earnings per share for the current year.

SGMO has been the subject of several recent analyst reports. StockNews.com cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, May 6th. Truist Financial reduced their price objective on Sangamo Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, April 5th. Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 7th. Finally, Wedbush restated a “neutral” rating on shares of Sangamo Therapeutics in a report on Friday, May 6th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sangamo Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $13.50.

Sangamo Therapeutics Profile (Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Featured Stories

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Rating).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.